肌层浸润性膀胱癌治疗与结局的性别和种族差异
多数为男性(73.4%)且仅接受膀胱切除术(69.0%)。女性90天死亡率高于男性(13.0% vs 11.6%,P=.009)且总生存更差;黑人患者接受最佳治疗的可能性更低(OR 0.15,95%CI 0.05-0.48)且90天死亡风险更高(OR 1.29,95%CI 1.11-1.50,P=.001)。
要点
- 女性肌层浸润性膀胱癌患者90天死亡率高于男性且总生存更差。
- 黑人患者接受最佳治疗(新辅助化疗+膀胱切除术)的可能性显著低于其他种族。
- 性别间接受最佳治疗无差异,但黑人患者90天死亡风险更高。
核心结论
- 性别间治疗差异不显著,但女性90天死亡率和总生存更差。
- 黑人患者接受最佳治疗可能性更低且90天死亡风险更高。
研究设计与样本
- 采用倾向性匹配比较性别间死亡结局,逻辑回归评估最佳治疗和死亡的预测因素。
主要发现
- 多数患者为男性(73.4%)且仅接受膀胱切除术(69.0%)。
- 倾向性匹配显示女性90天死亡率高于男性(13.0% vs 11.6%,P=.009)。
- 女性90天死亡OR 1.17(95%CI 1.08-1.27,P<.001),黑人OR 1.29(95%CI 1.11-1.50,P=.001)。
- 黑人接受最佳治疗OR 0.15(95%CI 0.05-0.48),性别间无差异(OR 1.01,95%CI 0.83-1.22)。
- Cox回归显示女性总生存更差(HR 0.92,95%CI 0.87-0.97)。
关键数值与推荐
- 最佳治疗定义为新辅助化疗+膀胱切除术。
- 女性90天死亡率13.0% vs 男性11.6%(P=.009)。
- 黑人接受最佳治疗OR 0.15(95%CI 0.05-0.48)。
- 女性90天死亡OR 1.17(95%CI 1.08-1.27,P<.001)。
- 黑人90天死亡OR 1.29(95%CI 1.11-1.50,P=.001)。
临床怎么用
- 临床应关注女性肌层浸润性膀胱癌患者术后90天死亡风险及总生存。
- 应识别并解决黑人患者接受最佳治疗的障碍。
局限性
- 需进一步研究确定导致女性和黑人患者结局更差的变量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify racial and sex disparities in the treatment and outcomes of muscle-invasive bladder cancer (MIBC) using a nationwide oncology outcomes database. METHODS: Using the National Cancer Database, we identified patients with muscle invasive bladder cancer from 2004 to 2014. Treatments analyzed included no treatment, cystectomy, neoadjuvant chemotherapy plus cystectomy ("optimal treatment"), cystectomy plus adjuvant chemotherapy, and chemoradiation. Propensity matching compared mortality outcomes between sexes. Logistic models evaluated predictors of receiving optimal treatment, as well as mortality. RESULTS: Forty seven thousand two hundred and twenty nine patients were identified. Most patients were male (73.4%) and underwent cystectomy alone (69.0%). Propensity score matching demonstrated increased 90-day mortality in women vs men (13.0% vs 11.6%, P = .009), despite adjusting for differences in treatments between sexes. Logistic regression models showed no difference in receipt of optimal treatment between sexes (odds ratio [OR] 1.01, 95% confidence interval [CI] 0.83-1.22) although black patients were less likely to receive optimal treatment (OR 0.15, 95% CI 0.05-0.48). Logistic regression models confirmed increased 90-day mortality in female (OR 1.17, CI 1.08-1.27, P < .001) and black (OR 1.29, CI 1.11-1.50, P = .001) patients. Females had a lower overall survival on Cox regression analysis (Hazard Ratio 0.92, 95% CI 0.87-0.97). CONCLUSION: While there do not appear to be significant treatment disparities between sexes, women experience higher 90-day mortality and lower overall survival. Black patients are less likely to receive optimal treatment and have a higher risk of 90-day mortality. Additional research is needed to determine the variables leading to worse outcomes in females and identify impediments to black patients receiving optimal treatment.
引用
- Marinaro J, Zeymo A, Egan J, et al. Sex and Racial Disparities in the Treatment and Outcomes of Muscle-invasive Bladder Cancer. Urology. 2020. PMID: 32810481. doi:10.1016/j.urology.2020.06.087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。